Literature DB >> 25644864

Asp58Ala is the predominant mutation of the TTR gene in Korean patients with hereditary transthyretin-related amyloidosis.

Mi-Ae Jang1, Ga Yeon Lee, Kihyun Kim, Seok-Jin Kim, Jung-Sun Kim, Soo-Youn Lee, Hee-Jin Kim, Eun-Seok Jeon.   

Abstract

Hereditary transthyretin (TTR)-related amyloidosis (ATTR) seems to be a rare autosomal-dominant inherited form of systemic amyloidosis. Studies indicate considerable heterogeneity in the disease's presentation and genotype; however, there is little data from Korea, where the prevalence of hereditary ATTR is very low. In this study, we investigated the phenotypic and genotypic spectra of hereditary ATTR in Korea. Direct sequencing analysis was performed to detect TTR gene mutations in amyloidosis patients whose results of TTR immunohistochemical staining were positive or equivocal. Clinical presentation was categorized as exclusively cardiac, exclusively neurologic, or mixed phenotype. Of 12 genetic tests performed, seven were positive for TTR mutations. D58A (c.173A>C) was the most common mutation in this study (57%, 4/7). The majority of those patients with hereditary ATTR had the mixed phenotype (86%, 6/7). The patients with D58A mutation had older ages of disease onset (median, 61 years vs. 42 years; P = 0.08), and a higher incidence of gastrointestinal involvement (75% vs. 0%; P = 0.03) than those with other identified TTR mutations. A significant male predominance was also noted in this study (P = 0.01).
© 2015 John Wiley & Sons Ltd/University College London.

Entities:  

Keywords:  D58A; Korea; TTR; hereditary; transthyretin-related amyloidosis

Mesh:

Year:  2015        PMID: 25644864     DOI: 10.1111/ahg.12101

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  4 in total

1.  Elderly patients with suspected Charcot-Marie-Tooth disease should be tested for the TTR gene for effective treatments.

Authors:  Takaki Taniguchi; Masahiro Ando; Yuji Okamoto; Akiko Yoshimura; Yujiro Higuchi; Akihiro Hashiguchi; Nozomu Matsuda; Mamoru Yamamoto; Eisuke Dohi; Makoto Takahashi; Masanao Yoshino; Taichi Nomura; Masaaki Matsushima; Ichiro Yabe; Yui Sanpei; Hiroyuki Ishiura; Jun Mitsui; Masanori Nakagawa; Shoji Tsuji; Hiroshi Takashima
Journal:  J Hum Genet       Date:  2022-01-14       Impact factor: 3.172

2.  Three Newly Recognized Likely Pathogenic Gene Variants Associated with Hereditary Transthyretin Amyloidosis.

Authors:  Jignesh K Patel; Andrew M Rosen; Adam Chamberlin; Benjamin Feldmann; Christian Antolik; Heather Zimmermann; Tami Johnston; Arvind Narayana
Journal:  Neurol Ther       Date:  2022-08-06

3.  Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review.

Authors:  Pranav Chandrashekar; Laith Alhuneafat; Meghan Mannello; Lana Al-Rashdan; Morris M Kim; Jason Dungu; Kevin Alexander; Ahmad Masri
Journal:  Circ Genom Precis Med       Date:  2021-08-31

4.  Characteristics of South Korean Patients with Hereditary Transthyretin Amyloidosis.

Authors:  Kyomin Choi; Jin Myoung Seok; Byoung Joon Kim; Young Cheol Choi; Ha Young Shin; Il Nam Sunwoo; Dae Seong Kim; Jung Joon Sung; Ga Yeon Lee; Eun Seok Jeon; Nam Hee Kim; Ju Hong Min; Jeeyoung Oh
Journal:  J Clin Neurol       Date:  2018-10       Impact factor: 3.077

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.